Omeros (NASDAQ:OMER – Get Free Report) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
A number of other research firms have also issued reports on OMER. Weiss Ratings raised Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective on shares of Omeros in a research report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $22.00 price objective on shares of Omeros in a research note on Wednesday, October 14th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.33.
Omeros Stock Performance
Omeros (NASDAQ:OMER – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The biopharmaceutical company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.04. The business had revenue of $35.93 million for the quarter, compared to analyst estimates of $37.28 million. As a group, equities analysts predict that Omeros will post -0.08 EPS for the current year.
Insider Transactions at Omeros
In other Omeros news, Director Arnold Hanish sold 10,000 shares of Omeros stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $18.95, for a total transaction of $189,500.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at approximately $94,750. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Peter Cancelmo sold 25,000 shares of the business’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $18.54, for a total transaction of $463,500.00. Following the completion of the sale, the vice president owned 200 shares in the company, valued at $3,708. This represents a 99.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 75,906 shares of company stock valued at $1,438,705. Company insiders own 10.50% of the company’s stock.
Hedge Funds Weigh In On Omeros
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Omeros in the 2nd quarter valued at $57,484,000. Corient Private Wealth LP acquired a new stake in Omeros in the 2nd quarter valued at approximately $6,274,000. State Street Corp lifted its position in shares of Omeros by 20.9% in the second quarter. State Street Corp now owns 2,319,906 shares of the biopharmaceutical company’s stock worth $22,062,000 after purchasing an additional 400,331 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Omeros by 151.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 395,032 shares of the biopharmaceutical company’s stock worth $7,521,000 after buying an additional 238,024 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Omeros during the second quarter valued at approximately $1,864,000. Institutional investors own 48.79% of the company’s stock.
Key Stories Impacting Omeros
Investors following OMER have been watching these stories:
- Positive Sentiment: Cantor Fitzgerald reiterated a Buy rating, adding to the positive analyst commentary. Cantor Fitzgerald remains a Buy
- Positive Sentiment: An earnings-call report highlighted growth for YARTEMLEA, which may support investor optimism about the product’s commercial prospects. Omeros earnings call highlights YARTEMLEA growth
- Negative Sentiment: HC Wainwright trimmed its FY2028 EPS forecast to $1.56 from $1.63, a modest offset to its higher estimates for other years. Analyst forecasts for Omeros
Omeros Company Profile
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.
Featured Stories
- Five stocks we like better than Omeros
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
